Theoretical studies on pyrimidine substituent derivatives as dual inhibitors of AP-1 and NF-κB

被引:0
|
作者
Li Qian
Si-Yan Liao
Zu-Liang Huang
Yong Shen
Kang-Cheng Zheng
机构
[1] Youjiang Medical College for Nationalities,Department of Chemistry
[2] Sun Yat-Sen University,School of Chemistry and Chemical Engineering
来源
关键词
Pyrimidine derivative; 3D-QSAR; Docking analysis; DNA; Activator protein-1; Nuclear factor kappa B;
D O I
暂无
中图分类号
学科分类号
摘要
Theoretical studies on the three-dimensional (3D) quantitative structure-activity relationship (QSAR) and mechanisms of action of a series of pyrimidine substituent derivatives as dual inhibitors of AP-1 and NF-κB were carried out using comparative molecular field analysis (CoMFA) and docking methods. The established 3D-QSAR model exhibits a satisfying statistical quality and prediction ability. Docking results show somewhat lower average values of the flexible and rigid energy scores in the chosen binding sites. The docking analysis offers appropriate orientations and conformations of these compounds at the binding sites to both AP-1 and NF-κB in good agreement with the 3D-QSAR model from CoMFA. The combined CoMFA and docking study suggests the following substituent selections: substituent R2 should be a kind of H–N–thienyl or CH3–N–thienyl group; substituent R5 should be a kind of COO–tBu or COOEt group; and substituent R4 should be a CH2CH3 or 2-thienyl group. The docking analysis also shows that the binding sites fall just at the joint regions between AP-1 (or NF-κB) and DNA, where these compounds can effectively prevent free AP-1 and NF-κB from binding to DNA, and this may be the reason that derivatives with pyrimidine substituents have an inhibition function. In addition, a very interesting finding was that the binding sites of both AP-1 and NF-κB have a common structural characteristic, thereby providing a reasonable explanation for the dual inhibition functions of these compounds towards both AP-1 and NF-κB. These theoretical results help to deepen our understanding of the inhibition mechanism of these pyrimidine substituent derivatives, and will aid in directing further drug-molecular design.
引用
收藏
页码:1139 / 1150
页数:11
相关论文
共 50 条
  • [41] Differential cytokine regulation by NF-κB and AP-1 in Jurkat T-cells
    Hazem Khalaf
    Jana Jass
    Per-Erik Olsson
    BMC Immunology, 11
  • [42] Oxidative stress and transcription factors AP-1 and NF-κB in humans lung tissue
    Crowther, A
    Rahman, I
    Antonicelli, F
    Jimenez, LA
    Salter, D
    MacNee, W
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A816 - A816
  • [43] Repression of NF-κB and activation of AP-1 enhance apoptosis in prostate cancer cells
    Zhang, Xiaoping
    Huang, Xu
    Olumi, Aria F.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (08) : 1980 - 1989
  • [44] Role of lung redox status in hyperoxic AP-1 and NF-κB activation with maturation
    Yang, G
    Dennery, PA
    PEDIATRIC RESEARCH, 2000, 47 (04) : 440A - 440A
  • [45] Induction of transcriptional activity of AP-1 and NF-κB in the gastric mucosa during aging
    Xiao, ZQ
    Majumdar, APN
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2000, 278 (06): : G855 - G865
  • [46] Cerulein activates NF-κB and AP-1 in isolated pancreatic acinar cells.
    Gukovsky, I
    Gukovskaya, AS
    Pandol, SJ
    GASTROENTEROLOGY, 1998, 114 (04) : A465 - A465
  • [47] Differential cytokine regulation by NF-κB and AP-1 in Jurkat T-cells
    Khalaf, Hazem
    Jass, Jana
    Olsson, Per-Erik
    BMC IMMUNOLOGY, 2010, 11
  • [48] Thioredoxin and its involvement in the redox regulation of transcription factors, NF-κB and AP-1
    Ohno, T
    Hirota, K
    Nakamura, H
    Masutani, H
    Sasada, T
    Yodoi, J
    OXYGEN HOMEOSTASIS AND ITS DYNAMICS, 1998, 1 : 450 - 456
  • [49] Role of activation of NF-κB and AP-1 by oxidative stress in atherosclerosis of diabetic patients
    Kim, CS
    Kim, DM
    Cho, MH
    Park, J
    Park, JS
    Nam, JY
    Ahn, CW
    Cha, BS
    Lim, SK
    Kim, KR
    Lee, HC
    Huh, KB
    DIABETOLOGIA, 2004, 47 : A452 - A453
  • [50] Inhibition of NF-κB and AP-1 activation by R- and S-flurbiprofen
    Tegeder, I
    Niederberger, E
    Israr, E
    Gühring, H
    Brune, K
    Euchenhofer, C
    Grösch, S
    Geisslinger, G
    FASEB JOURNAL, 2001, 15 (01): : 2 - 4